Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04533191 · ClinicalTrials.gov registry record
Binocular Custom Vision Utilizing The Light Adjustable Lens (LAL)
A clinical trial of Cataract and Pseudophakia, sponsored by Vance Thompson Vision.
- Completed
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT04533191: Completed study of Cataract and Pseudophakia, sponsored by Vance Thompson Vision.
NCT04533191 is a study of Cataract and Pseudophakia that has completed, run by Vance Thompson Vision. The registered enrollment target is 25 participants, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04533191, a study of Cataract and Pseudophakia, has completed, sponsored by Vance Thompson Vision.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this investigator initiated study (IIT-001) is to obtain data on clinical methods which can be used during the examination of patients desiring binocular custom vision with the Light Adjustable Lens (LAL). An analysis of the collected data will be performed to determine whether these clinical assessments can be used by doctors to enhance their patient's clinical outcome.
Conditions Studied
Interventions
- PROCEDURE LAL IOL lens
Study Locations (1)
South Dakota
- Vance Thompson Vision - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2021-02-01 |
What the finished NCT04533191 record still lists
NCT04533191 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 228-participant average among 83 other Cataract trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Cataract appearing as the primary indexed condition, and to 1 intervention - of which LAL IOL lens is the first listed.
NCT04533191 reports a single indexed study location in South Dakota.
Frequently Asked Questions
What is clinical trial NCT04533191 about?
NCT04533191 is a clinical study titled "Binocular Custom Vision Utilizing The Light Adjustable Lens (LAL)". The objective of this investigator initiated study (IIT-001) is to obtain data on clinical methods which can be used during the examination of patients desiring binocular custom vision with the Light Adjustable Lens (LAL). An analysis of the collected data will be performed to determine whether thes...
What is the current status of trial NCT04533191?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2020-09-01. Estimated completion is 2021-02-01.
What conditions does trial NCT04533191 study?
This clinical trial studies the following conditions: Cataract, Pseudophakia.
What interventions are being tested in trial NCT04533191?
The interventions under investigation include: LAL IOL lens (PROCEDURE).
Who is sponsoring clinical trial NCT04533191?
This trial is sponsored by Vance Thompson Vision, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04533191 being conducted?
This trial has 1 study location across South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04533191's enrollment target sits among peer trials
25 77th of 83 higher than 6 of 83 other Cataract trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cataract trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
RECRUITING
-
Effective Phaco Time and Endothelial Cell Loss When Using Veritas
RECRUITING
-
Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety and Workflow Study
RECRUITING · NA
-
Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC
RECRUITING · Phase 1
-
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
RECRUITING · Phase 3
-
Unity VCS: A Comparison Study Evaluating Corneal Clarity and Thickness
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI